Is SLN or ZLAB more profitable?

Zai Lab has a net margin of -41.86% compared to Silence Therapeutics' net margin of -8,943.86%. Zai Lab's return on equity of -27.43% beat Silence Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silence Therapeutics -8,943.86% -106.94% -47.99% Zai Lab -41.86% -27.43% -16.72%

Silence Therapeutics (SLN) Competitors

$13.02 -0.29 (-2.18%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$13.02 +0.01 (+0.04%)

As of 09/11/2026 07:30 PM Eastern

Compare

SLN vs. QURE, CLDX, NAMS, IMNM, and ZLAB

Should you buy Silence Therapeutics stock or one of its competitors? Silence Therapeutics's main competitors and comparable companies include uniQure (QURE), Celldex Therapeutics (CLDX), NewAmsterdam Pharma (NAMS), Immunome (IMNM), and Zai Lab (ZLAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Silence Therapeutics compare to uniQure?

Silence Therapeutics (NASDAQ:SLN) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, uniQure had 2 more articles in the media than Silence Therapeutics. MarketBeat recorded 3 mentions for uniQure and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.18 beat uniQure's score of 0.85 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
uniQure	Positive

uniQure has a net margin of -1,350.73% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -106.94% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
uniQure	-1,350.73%	-111.96%	-29.01%

Silence Therapeutics presently has a consensus target price of $53.50, suggesting a potential upside of 310.91%. uniQure has a consensus target price of $65.00, suggesting a potential upside of 46.03%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Silence Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
uniQure	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Silence Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A
uniQure	$18.67M	165.35	-$198.97M	-$4.01	N/A

Silence Therapeutics has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market. Comparatively, uniQure has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

Silence Therapeutics beats uniQure on 11 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Celldex Therapeutics?

Celldex Therapeutics (NASDAQ:CLDX) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Celldex Therapeutics currently has a consensus target price of $56.42, suggesting a potential upside of 52.89%. Silence Therapeutics has a consensus target price of $53.50, suggesting a potential upside of 310.91%. Given Silence Therapeutics' higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

98.7% of Silence Therapeutics shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Celldex Therapeutics had 4 more articles in the media than Silence Therapeutics. MarketBeat recorded 5 mentions for Celldex Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.18 beat Celldex Therapeutics' score of 0.78 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Celldex Therapeutics	Positive
Silence Therapeutics	Positive

Celldex Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Celldex Therapeutics' return on equity of -52.35% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

Celldex Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Silence Therapeutics has lower revenue, but higher earnings than Celldex Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,881.66	-$258.76M	-$4.35	N/A
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A

Summary

Celldex Therapeutics beats Silence Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and Silence Therapeutics (NASDAQ:SLN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

NewAmsterdam Pharma has a net margin of -3,644.21% compared to Silence Therapeutics' net margin of -8,943.86%. NewAmsterdam Pharma's return on equity of -34.81% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%

NewAmsterdam Pharma has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 12.7% of NewAmsterdam Pharma shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, NewAmsterdam Pharma had 17 more articles in the media than Silence Therapeutics. MarketBeat recorded 18 mentions for NewAmsterdam Pharma and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.18 beat NewAmsterdam Pharma's score of 0.44 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
Silence Therapeutics	Positive

NewAmsterdam Pharma presently has a consensus price target of $49.73, indicating a potential upside of 118.10%. Silence Therapeutics has a consensus price target of $53.50, indicating a potential upside of 310.91%. Given Silence Therapeutics' higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Silence Therapeutics has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	121.13	-$203.82M	-$2.16	N/A
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A

Summary

NewAmsterdam Pharma and Silence Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Silence Therapeutics compare to Immunome?

Silence Therapeutics (NASDAQ:SLN) and Immunome (NASDAQ:IMNM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by insiders. Comparatively, 7.2% of Immunome shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Silence Therapeutics has higher earnings, but lower revenue than Immunome. Silence Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A
Immunome	$6.94M	403.75	-$212.39M	-$2.53	N/A

Silence Therapeutics currently has a consensus price target of $53.50, suggesting a potential upside of 310.91%. Immunome has a consensus price target of $34.64, suggesting a potential upside of 40.40%. Given Silence Therapeutics' higher possible upside, equities research analysts plainly believe Silence Therapeutics is more favorable than Immunome.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Immunome	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Immunome has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Immunome's return on equity of -50.56% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Immunome	N/A	-50.56%	-46.93%

Silence Therapeutics has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, Immunome has a beta of 2.13, suggesting that its share price is 113% more volatile than the broader market.

In the previous week, Immunome had 8 more articles in the media than Silence Therapeutics. MarketBeat recorded 9 mentions for Immunome and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.18 beat Immunome's score of 1.08 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
Immunome	Positive

Summary

Immunome beats Silence Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Silence Therapeutics compare to Zai Lab?

Silence Therapeutics (NASDAQ:SLN) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment and valuation.

Zai Lab has a net margin of -41.86% compared to Silence Therapeutics' net margin of -8,943.86%. Zai Lab's return on equity of -27.43% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Zai Lab	-41.86%	-27.43%	-16.72%

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 41.7% of Zai Lab shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Comparatively, 4.9% of Zai Lab shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Silence Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,399.88	-$88.61M	-$1.28	N/A
Zai Lab	$460.16M	5.97	-$175.54M	-$1.71	N/A

In the previous week, Zai Lab had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 2 mentions for Zai Lab and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 1.18 beat Zai Lab's score of 0.87 indicating that Silence Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Silence Therapeutics	Positive
Zai Lab	Positive

Silence Therapeutics presently has a consensus target price of $53.50, suggesting a potential upside of 310.91%. Zai Lab has a consensus target price of $37.25, suggesting a potential upside of 54.31%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Silence Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Silence Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Zai Lab has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Summary

Silence Therapeutics beats Zai Lab on 9 of the 15 factors compared between the two stocks.

Get Silence Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLN vs. The Competition

Export

Metric	Silence Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$783.92M	$3.85B	$7.16B	$12.85B
Dividend Yield	N/A	3.65%	2.57%	11.17%
P/E Ratio	-10.17	14.18	274.94	25.36
Price / Sales	1,399.88	1,374.99	686.57	116.78
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	9.86	15.12	10.33	6.20
Net Income	-$88.61M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-10.76%	-4.34%	-3.32%	-2.35%
1 Month Performance	-6.80%	0.54%	-0.53%	-3.23%
1 Year Performance	188.69%	40.74%	23.51%	8.79%

Silence Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLN Silence Therapeutics	3.0363 of 5 stars	$13.02 -2.2%	$53.50 +310.9%	+188.7%	$783.92M	$560K	N/A	88	Positive News
QURE uniQure	3.5436 of 5 stars	$45.68 +2.7%	$65.00 +42.3%	+169.9%	$3.17B	$16.10M	N/A	500
CLDX Celldex Therapeutics	1.9062 of 5 stars	$39.12 -1.4%	$56.08 +43.4%	+50.9%	$3.07B	$1.54M	N/A	150	News Coverage Positive News Analyst Forecast Gap Down
NAMS NewAmsterdam Pharma	2.8705 of 5 stars	$25.63 +0.9%	$49.73 +94.0%	-5.7%	$3.06B	$22.50M	N/A	4	News Coverage Analyst Forecast High Trading Volume
IMNM Immunome	3.1156 of 5 stars	$26.81 +0.2%	$34.64 +29.2%	+167.9%	$3.05B	$6.94M	N/A	40	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLN) was last updated on 9/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silence Therapeutics (SLN) Competitors

SLN vs. QURE, CLDX, NAMS, IMNM, and ZLAB

How does Silence Therapeutics compare to uniQure?

Summary

How does Silence Therapeutics compare to Celldex Therapeutics?

Summary

How does Silence Therapeutics compare to NewAmsterdam Pharma?

Summary

How does Silence Therapeutics compare to Immunome?

Summary

How does Silence Therapeutics compare to Zai Lab?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silence Therapeutics (SLN) Competitors

SLN vs. QURE, CLDX, NAMS, IMNM, and ZLAB

How does Silence Therapeutics compare to uniQure?

Does the media refer more to SLN or QURE?

Is SLN or QURE more profitable?

Do analysts recommend SLN or QURE?

Do insiders & institutionals hold more shares of SLN or QURE?

Which has preferable earnings and valuation, SLN or QURE?

Which has more volatility & risk, SLN or QURE?

Summary

How does Silence Therapeutics compare to Celldex Therapeutics?

Do analysts rate CLDX or SLN?

Do institutionals & insiders hold more shares of CLDX or SLN?

Does the media prefer CLDX or SLN?

Is CLDX or SLN more profitable?

Which has more risk and volatility, CLDX or SLN?

Which has higher earnings and valuation, CLDX or SLN?

Summary

How does Silence Therapeutics compare to NewAmsterdam Pharma?

Is NAMS or SLN more profitable?

Which has more volatility & risk, NAMS or SLN?

Do insiders and institutionals believe in NAMS or SLN?

Does the media prefer NAMS or SLN?

Do analysts recommend NAMS or SLN?

Which has better valuation & earnings, NAMS or SLN?

Summary

How does Silence Therapeutics compare to Immunome?

Do insiders and institutionals believe in SLN or IMNM?

Which has preferable valuation & earnings, SLN or IMNM?

Do analysts rate SLN or IMNM?

Is SLN or IMNM more profitable?

Which has more volatility & risk, SLN or IMNM?

Does the media refer more to SLN or IMNM?

Summary

How does Silence Therapeutics compare to Zai Lab?

Is SLN or ZLAB more profitable?

Do institutionals & insiders hold more shares of SLN or ZLAB?

Which has better valuation and earnings, SLN or ZLAB?

Does the media refer more to SLN or ZLAB?

Do analysts prefer SLN or ZLAB?

Which has more volatility and risk, SLN or ZLAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLN vs. The Competition

Silence Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools